Xilio Therapeutics (XLO) Other financing activities (2020 - 2026)
Xilio Therapeutics (XLO) reported Other financing activities of $1000.0 for Q1 2026, down 80.0% on a YoY basis from $5000.0 in Q1 2025, and down 100.0% sequentially from $35.8 million in Q4 2025.
Xilio Therapeutics (XLO) Other financing activities (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Other financing activities data on file, last reported at $1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 80.0% year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at $35.8 million (up 945.9% YoY), and the FY2025 full-year result was $35.8 million, up 52588.24% from the prior year.
- Other financing activities slipped to $1000.0 in Q1 2026, from $35.8 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $35.8 million in Q4 2025 to a low of -$4.3 million in Q2 2024.
- A 5-year average of $3.3 million and a median of $5000.0 in 2025 frame the typical range for Other financing activities.
- Peak annual rise in Other financing activities reached 56755.56% in 2025, while the deepest fall reached 99.88% in 2025.
- Tracing XLO's Other financing activities over 5 years: stood at $16000.0 in 2022, then soared by 1062.5% to $186000.0 in 2023, then slumped by 66.13% to $63000.0 in 2024, then soared by 56755.56% to $35.8 million in 2025, then sank by 100.0% to $1000.0 in 2026.
- Business Quant data shows XLO's Other financing activities at $1000.0 in Q1 2026, $35.8 million in Q4 2025, and $4000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 35.82 Mn |
| Dec 31, 2025 | 35.82 Mn |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | 186,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | -132,000.00 |
| Sep 30, 2023 | -132,000.00 |